Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Editas Medicine (EDIT) Long-Term Investments: 2020-2024

Historic Long-Term Investments for Editas Medicine (EDIT) over the last 3 years, with Jun 2024 value amounting to $39.2 million.

  • Editas Medicine's Long-Term Investments fell 18.50% to $39.2 million in Q2 2024 from the same period last year, while for Jun 2024 it was $39.2 million, marking a year-over-year decrease of 18.50%. This contributed to the annual value of $104.0 million for FY2023, which is 11.74% up from last year.
  • Per Editas Medicine's latest filing, its Long-Term Investments stood at $39.2 million for Q2 2024, which was down 51.37% from $80.6 million recorded in Q1 2024.
  • In the past 5 years, Editas Medicine's Long-Term Investments ranged from a high of $120.1 million in Q4 2021 and a low of $39.2 million during Q2 2024.
  • Moreover, its 3-year median value for Long-Term Investments was $79.3 million (2022), whereas its average is $75.7 million.
  • In the last 5 years, Editas Medicine's Long-Term Investments soared by 115.65% in 2021 and then crashed by 40.68% in 2022.
  • Quarterly analysis of 5 years shows Editas Medicine's Long-Term Investments stood at $109.7 million in 2020, then rose by 9.49% to $120.1 million in 2021, then decreased by 22.47% to $93.1 million in 2022, then rose by 11.74% to $104.0 million in 2023, then decreased by 18.50% to $39.2 million in 2024.
  • Its Long-Term Investments was $39.2 million in Q2 2024, compared to $80.6 million in Q1 2024 and $104.0 million in Q4 2023.